GlassScriptPhysician profile
Wassim E Nona
NPI 1629051107
$10,701.85
in general payments reported to CMS, 2019-2025
24 companies · $833 in 2025
The $833 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,127 · 2020: $536 · 2021: $1,096 · 2022: $3,021 · 2023: $919 · 2024: $1,169 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,003.75 | 2019-2025 | Amplatzer Amulet, Ensite Precision, Gallant |
| Medtronic, INC. | $2,506.66 | 2021-2025 | Corevalve Evolut R, Symplicity G3 |
| Medtronic Vascular, INC. | $1,802.38 | 2019 | |
| Edwards Lifesciences Corporation | $1,198.11 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Kestra Medical Technology Services, INC. | $389.83 | 2022-2025 | Assure Wcd |
| Inari Medical, INC. | $346.19 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| E.R. Squibb & Sons, L.L.C. | $175.83 | 2019-2024 | Camzyos |
| Genzyme Corporation | $166.85 | 2019-2022 | |
| Abiomed | $144.93 | 2024 | Impella |
| Novartis Pharmaceuticals Corporation | $140.40 | 2019-2025 | |
| Penumbra, INC. | $134.43 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.00 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $99.52 | 2019-2020 | |
| Siemens Medical Solutions USA, INC. | $98.17 | 2019-2020 | |
| Pfizer INC. | $78.24 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $70.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.91 | 2024-2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $40.62 | 2019 | |
| Heartflow, INC. | $37.59 | 2019 | |
| Impulse Dynamics (USA) INC. | $30.87 | 2023 | Optimizer |
| Bridgebio Pharma, INC. | $18.43 | 2025 | Attruby |
| Amgen INC. | $16.64 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.02 | 2023 | Inpefa |
| Irhythm Technologies, INC. | $14.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wassim Nona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.